We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Injectable Breast ‘Implant’ Offers Alternative to Traditional Surgeries

By HospiMedica International staff writers
Posted on 13 Jan 2026

Breast cancer surgery can require the removal of part or all of the breast, leaving patients with difficult decisions about reconstruction. More...

Current reconstructive options often rely on prosthetic implants or tissue grafts taken from other parts of the body, which can involve significant scarring, long recovery times, and post-surgical complications. Researchers have now developed an injectable, skin-derived material designed to restore breast volume after tumor removal while reducing scarring and healing time.

In the research led by Seoul National University (Seoul, Republic of Korea), the team focused on acellular dermal matrix (ADM), a processed form of human skin that retains structural and biological components such as collagen, elastin, and growth factors essential for tissue repair. To create an injectable version, donated human skin was decellularized, frozen, and pulverized into fine particles, which were then mixed with water to form a thick paste. Unlike traditional sheet-based ADM products used in plastic and reconstructive surgery, this paste can be injected directly into tissue defects to act as a space-filling scaffold.

The injectable ADM paste was tested in rats to evaluate biocompatibility and long-term tissue response. Animals receiving the new paste showed no adverse health effects over six months. Compared with two commercially available ADM products, the injectable paste produced thinner encapsulating tissue layers around the implant. Thinner tissue layers are clinically desirable, as they lower the risk of complications such as infection, hematoma, and capsular contracture.

The findings, reported in ACS Applied Bio Materials, suggest that an injectable, acellular skin-derived matrix could offer a safer and less invasive alternative for reconstructive breast surgery. By promoting blood vessel growth and tissue remodeling while minimizing inflammation, the material may improve cosmetic outcomes and long-term comfort for patients. Further studies, including longer-term safety testing and more complex preclinical models, are required before clinical use. The researchers plan to refine the material and evaluate its performance in settings that more closely mimic human breast reconstruction.

“By promoting blood vessel growth and tissue remodeling while keeping inflammation low and reducing capsular contracture, the injectable acellular matrix could make breast reconstruction safer, less invasive, and more accessible, thereby improving long-term comfort and cosmetic outcomes for patients,” said Pham Ngoc Chien, one of the study’s lead researchers.

Related Links:
Seoul National University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.